MDT
NYSEMedtronic plc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Price$81.64-13.94 (-14.58%)
2026-03-042026-06-05
News · 26 weeks82-33%
2025-12-142026-06-07
Mix4990d
- Other23(47%)
- Insider19(39%)
- SEC Filings4(8%)
- Analyst2(4%)
- Offering1(2%)
Latest news
25 items- ANALYSTMedtronic upgraded by BTIG Research with a new price targetBTIG Research upgraded Medtronic from Neutral to Buy and set a new price target of $90.00
- PRMedtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United StatesCompany also announces 510(k) pending for LigaSure™ RAS Maryland instrument on the Hugo RAS system, and 510(k) clearance for ProGrip™ Advanced self-gripping polypropylene mesh for use in robotic-assisted ventral hernia repair surgeriesGALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced significant milestones to unlock expanded indications for the Hugo™ robotic-assisted surgery (RAS) system in the United States and to shape the future of surgery.General surgery indication including hernia repair — 510(k) clearance submittedEmbrace Gynecology Investigational Device Exemption (IDE) clinical study — completed enrollmentGyn
- PRMedtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadensInvestments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of technologiesGALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography (ICE) catheter technologies. ICE catheters provide real-time, high-resolution imaging of the heart during electrophysiology (EP) procedures for cardiac arrhythmias such as atrial fibrillation (Afib). Medtronic intends to integrate ICE into the Affera
- SECMedtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Medtronic plc (0001613103) (Filer)
- PRMedtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 yearsDisciplined execution and portfolio strength position Medtronic for continued momentum into fiscal year 2027GALWAY, Ireland, June 3, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which ended April 24, 2026.Q4 Key HighlightsRevenue of $9.8 billion, increased 9.9% as reported and 6.6% organic, 90 basis points ahead of Q4 implied guidanceGAAP diluted EPS of $0.96; non-GAAP diluted EPS of $1.55, ahead of guidanceCardiac Ablation Solutions revenue increased 78% globally, including 124% U.S. growth, gaining an additional 8 points of U.S. shareCardiovascular grew 10.1%, led
- PRmorph Launches the World's First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World ApplicationsBacked by 8VC, Pharrell Williams, Copper, Harvey Spevak of Equinox Group, Qubit Ventures, Valia Ventures, and Blue Lion morph today launches a physically intelligent soft robotics platform that designs and manufactures what it calls "soft robotic cells," a term coined by the company. Founded by Dr. Jean Nehme, a former reconstructive surgeon who founded and exited surgical AI company Digital Surgery, morph's soft robotics platform marks a new frontier in physical AI and next-generation robotics by embedding sensing and adaptive control directly into reconfigurable deformable materials, enabling real‑time change in morphology and stiffness. morph is helping define a new category of embodie
- INSIDERSVP, Chief HR Officer Walter Matthew R. converted options into 9,149 units of Ordinary Shares, increasing direct ownership by 28% to 41,529 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDEREVP & Pres Neuroscience Wall Brett A. converted options into 26,907 units of Ordinary Shares, increasing direct ownership by 49% to 82,183 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERChairman and CEO Martha Geoffrey converted options into 94,963 units of Ordinary Shares, increasing direct ownership by 38% to 343,099 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDEREVP, Pres MedSurg and Americas Marinaro Michael converted options into 18,994 units of Ordinary Shares, increasing direct ownership by 37% to 70,593 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDEREVP & President Cardiovascular Kiil Harry Skip converted options into 15,195 units of Ordinary Shares, increasing direct ownership by 46% to 48,233 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERChief Accounting Officer Blomquist Denise L. converted options into 1,712 units of Ordinary Shares, increasing direct ownership by 13% to 14,974 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- SECSEC Form SD filed by Medtronic plc.SD - Medtronic plc (0001613103) (Filer)
- ANALYSTGoldman resumed coverage on Medtronic with a new price targetGoldman resumed coverage of Medtronic with a rating of Neutral and set a new price target of $84.00
- PRMedtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic painAcquisition will enhance Medtronic's Neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) technology, enabling earlier intervention for chronic pain sufferersGALWAY, Ireland, May 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global healthcare technology leader, today announced its intent to acquire SPR Therapeutics, Inc. (SPR), a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for chronic pain management. The transaction consists of an upfront cash payment of approximately $650 million for all the outstanding equity in SPR. The acquisition continues Medtronic's momentum in
- SECMedtronic plc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Medtronic plc (0001613103) (Filer)
- PROrchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesOrchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE:MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial presentation at major cardiology conference in Q2 2027 and subsequent marketing application submission to FDA and global regulatory agencies, assuming primary endpoints are met FDA granted a second Breakthrough Device Designation ("BDD") for AVIM Therapy specific to patients with uncontrolled hypertension despite the use of anti-hypertensive medications, and an indication for a pacemakerVirtue Trial sites progressing with site activation and patient enrollment acceleration continuing t
- PROrchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026 Orchestra BioMed and Medtronic plc. (NYSE:MDT, "Medtronic")), the Company's strategic collaborator for the BACKBEAT Trial, intend to submit primary endpoint results for consideration as a late-breaker at a major cardiology conference in Q2 2027Medtronic plans to submit AVIM Therapy-related marketing application for FDA approval after primary endpoint data analyses and reports are complete and pursue subsequent global regulatory approvals, assuming primary safety and efficacy endpoints are met NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, I
- PROrchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra BioMed's future revenue as well as equityFunding supports continued execution of Orchestra BioMed's pivotal trials for Atrioventricular Interval Modulation Therapy ("AVIM Therapy") and Virtue Sirolimus AngioInfusion Balloon ("Virtue SAB") This payment, together with a $20 million investment from Medtronic (NYSE:MDT) announced separately, represents a total of $35 million in fresh strategic capital received on May 1, 2026 under previously disclosed agreements NEW HOPE, Pa., Ma
- PROrchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing AgreementPayment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") evaluating Atrioventricular Interval Modulation Therapy ("AVIM Therapy") in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and MedtronicThis payment, together with $15 million received from Ligand and announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the
- INSIDERSVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 35 units of Ordinary Shares, decreasing direct ownership by 0.11% to 32,380 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- PRFDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM TherapyAtrioventricular Interval Modulation ("AVIM") Therapy Food and Drug Administration ("FDA") Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at increased cardiovascular risk and the specific pacemaker-indicated population being evaluated in the BACKBEAT TrialThe addressable U.S. patient population for AVIM Therapy, based on the indications for use specified in its Breakthrough Device Designations, comprises over 7.7 million adults with hypertension despite medicationBreakthrough Device Designation supports favorable reimbursement pathways, including potential eligibility for New Technology Add-on Payment ("NTAP") and Tr
- INSIDERChief Accounting Officer Blomquist Denise L. was granted 1,508 units of Ordinary Shares and covered exercise/tax liability with 318 units of Ordinary Shares, increasing direct ownership by 10% to 13,262 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Nabel Elizabeth G was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 11% to 19,584 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Powell Kendall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 51,380 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
MDT FAQ
6 questionsWhat does Medtronic plc. do?
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered...Where does MDT stock trade?
Medtronic plc. (MDT) is listed on NYSE.What sector and industry is MDT in?
Medtronic plc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about MDT?
Medtronic plc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy on 2026-06-04.What companies are similar to MDT?
Notable peers in the same industry include MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation), SLNO (Soleno Therapeutics Inc.). Compare MDT side-by-side with any of them on Quantisnow.How can I track MDT on Quantisnow?
Quantisnow aggregates Medtronic plc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDT to receive live email and push alerts on every new disclosure.